Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering's Revenue history spans 3 years, with the latest figure at $455.0 for Q4 2022.

  • On a quarterly basis, Revenue fell 99.76% to $455.0 in Q4 2022 year-over-year; TTM through Sep 2023 was $455.0, a 99.91% decrease, with the full-year FY2022 number at $316952.0, down 84.76% from a year prior.
  • Revenue came in at $455.0 for Q4 2022, down from $38380.0 in the prior quarter.
  • The five-year high for Revenue was $748200.0 in Q1 2021, with the low at $455.0 in Q4 2022.
  • Historically, Revenue has averaged $384127.1 across 3 years, with a median of $480835.0 in 2020.
  • Biggest five-year swings in Revenue: soared 37.27% in 2021 and later crashed 99.76% in 2022.
  • Year by year, Revenue stood at $665080.0 in 2020, then crashed by 71.49% to $189591.0 in 2021, then tumbled by 99.76% to $455.0 in 2022.
  • Business Quant data shows Revenue for IMRX at $455.0 in Q4 2022, $38380.0 in Q3 2022, and $94419.0 in Q2 2022.